In my work, I always try to combine fundamental analysis and technical analysis.
They are both important, especially on a topic as important as the covid vaccine.
Johnson & Johnson is about to be marketed, after the approval of the EMA on 11 March.
Exactly after the announcement, I bought the stock.
The JnJ vaccine has a much lower distribution cost than Pfizer since it can be stored at refrigerator temperatures, like AstraZeneca.
The difference is in the prestige and history that the company has.
Moreover, the share according to the average of analysts, still has ample room for growth, with an average target of $ 185 and a second "high" at $ 200.
Technically speaking, the price bounced off the bullish support trendline on Thursday, March 4th, and then broke the resistance trendline on the 12th, exactly the day after the announcement of the EMA's approval.
The trend is clearly bullish, but, even keeping in mind the analysts' opinion, I believe the first target in area 170 is more likely.
If everything goes well with the vaccine, the analyst targets could be greatly raised.
It is a different trade, to be constantly monitored with a trailing stop, in case there will be any hitches or cases of a block, as happened for AstraZeneca. Such an open market scenario would cause a crash, so you have to be ready to get out quickly.
Lazy Bull
1st target: 170
2nd target: 180
3rd target: 200
DISCLAIMER: I am not a financial advisor nor a CPA. These posts, videos, and any other contents are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
They are both important, especially on a topic as important as the covid vaccine.
Johnson & Johnson is about to be marketed, after the approval of the EMA on 11 March.
Exactly after the announcement, I bought the stock.
The JnJ vaccine has a much lower distribution cost than Pfizer since it can be stored at refrigerator temperatures, like AstraZeneca.
The difference is in the prestige and history that the company has.
Moreover, the share according to the average of analysts, still has ample room for growth, with an average target of $ 185 and a second "high" at $ 200.
Technically speaking, the price bounced off the bullish support trendline on Thursday, March 4th, and then broke the resistance trendline on the 12th, exactly the day after the announcement of the EMA's approval.
The trend is clearly bullish, but, even keeping in mind the analysts' opinion, I believe the first target in area 170 is more likely.
If everything goes well with the vaccine, the analyst targets could be greatly raised.
It is a different trade, to be constantly monitored with a trailing stop, in case there will be any hitches or cases of a block, as happened for AstraZeneca. Such an open market scenario would cause a crash, so you have to be ready to get out quickly.
Lazy Bull
1st target: 170
2nd target: 180
3rd target: 200
DISCLAIMER: I am not a financial advisor nor a CPA. These posts, videos, and any other contents are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
Check my PnL and much more ----> Website
The news of the Johnson & Johnson vaccine block in some US states caused a sharp drop in the price, which could and could still turn into a collapse capable of reaching $ 150 or more.
I had already said that I would have managed the position with a trailing stop, unfortunately on the day of April 13th JNJ opened with a GAP of -3.17% after the day of the 12th had closed positive, "holding" the EMA 50.
The GAP slightly increased my loss, which however remained modest, having a good entry point.
The price then reacted for two consecutive sessions, creating minor support in the 156.53 area.
As far as I am concerned, it is not the case to enter at the moment, considering the delicate moment, where any further negative news could cause the title to fall even heavily.
Interesting new entry levels should the downtrend continue: $ 151 and $ 146.
If instead, the situation improves it will be interesting to see the price reaction once the bearish trendline is broken.
Lazy Bull